Targeted Covalent Inhibitors for Drug Design
The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Abstract
In contrast to the traditional mechanism of drug action that relies on the reversible, noncovalent interaction of a ligand with its biological target, a targeted covalent inhibitor (TCI) is designed such that the initial, reversible association is followed by the formation of a covalent bond between an electrophile on the ligand and a nucleophilic center in the protein. Although this approach offers a variety of potential benefits (high potency and extended duration of action), concerns over the possible toxicological consequences of protein haptenization have hindered the development of the TCI concept. Recently, approaches to mitigate the risk of serious adverse reactions to this new class of agent have emerged, thus stimulating interest in the field and leading to authorization of the first cadre of TCIs to be marketed. The covalent inhibitor approach is rapidly gaining acceptance as a valuable tool in drug discovery, and is poised to make a major impact on the design of enzyme inhibitors and receptor modulators.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, the oxidation of drugs such as furosemide, isoniazid, acetaminophen, halothane, and model hepatotoxins via cytochrome P-450 can lead to hepatotoxic effects in animals and humans [131, 132].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [132]
Citations
Cites
The growing applications of click chemistry
Moses, J. E., & Moorhouse, A. D. (2007) · Chem. Soc. Rev. · doi:10.1039/b613014n · Cited by 2,367
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Self-citationCommon and Uncommon Cytochrome P450 Reactions Related to Metabolism and Chemical Toxicity
Guengerich, F. P. (2001) · Chemical Research in Toxicology · doi:10.1021/tx0002583 · Cited by 1,655
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases
Powers, J. C., Asgian, J. L., Ekici, Ö. D., & James, K. E. (2002) · Chemical Reviews · doi:10.1021/cr010182v · Cited by 1,090
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Kuhn, D. J., Chen, Q., Voorhees, P. M., Strader, J. S., Shenk, K. D., Sun, C. M., Demo, S. D., Bennett, M. K., van Leeuwen, F. W. B., Chanan-Khan, A. A., et al. (2007) · Blood · doi:10.1182/blood-2007-01-065888 · Cited by 768
Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., & Baillie, T. A. (2004) · Chemical Research in Toxicology · doi:10.1021/tx034170b · Cited by 706
Self-citationStepan, A. F., Walker, D. P., Bauman, J., Price, D. A., Baillie, T. A., Kalgutkar, A. S., & Aleo, M. D. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200168d · Cited by 698
Self-citation
Research works printed but not linked: 7
- Parmar S., 2014, Pharm. Ther., 39, 483
- Johansson M. H., 2012, Mini-Rev. Med. Chem., 12, 1330
- Campuzano I. D. G., 2015, J. Biomol. Screening, 1
- Guerciolini R., 1997, Int. J. Obes., 21, 12
- Kumar S., 2008, Curr. Opin. Drug Discovery Dev., 11, 43
- Strelevitz T. J., 2015, Drug Metab. Rev., 47, 59
- The Wall Street Journal December 2 2015.
Cited by
Items 401–500 of 618
Beyond structural analysis of molecular enzyme-inhibitor interactions
Welborn, V. V. (2022) · Electronic Structure · doi:10.1088/2516-1075/ac509f · Cited by 5
Assembly‐Glued Ligands and Warheads for Hypoxia‐Activatable Supramolecular Covalent Inhibitors
Hu, B., Qin, W., Wang, Y., Zhang, Z., Chen, N., Wang, H., Li, G., Shi, Y., & Yu, Z. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202411179 · Cited by 5
Modification of proteins with azobenzene crosslinkers using reversible covalent bonds
Yasuike, N., Kachi-Terajima, C., Karin, A., Mino, T., & Woolley, G. A. (2022) · Organic & Biomolecular Chemistry · doi:10.1039/d2ob01656g · Cited by 5
He, L., Zhou, G., Sofiyev, V., Garcia, E., Nguyen, N., Li, K. H., & Gochin, M. (2022) · Viruses · doi:10.3390/v14122703 · Cited by 5
Lee, S. B., Yu, J., Kim, H., Kim, K. W., Jeong, J. W., Kim, Y. L., Park, S. J., Koo, T., Lee, C., Hong, K. B., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01926 · Cited by 5
Io, W.-S., & Wang, T. A. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00102 · Cited by 5
Xue, L., Liu, W., Li, S., Duchemin, N., Lou, M., Yuan, J., Zhang, H., Chen, J., Yu, W., Yang, K., et al. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00138 · Cited by 5
Localization of Sites of Osimertinib Action in Rat Intestine, Skin, and Lung by Immunohistochemistry
Yamamoto, Y., Saita, T., Kataoka, H., Sogawa, R., Kimura, S., Kimura, S. H., Shimanoe, C., & Shin, M. (2023) · ACTA HISTOCHEMICA ET CYTOCHEMICA · doi:10.1267/ahc.23-00055 · Cited by 5
Synthesis and bioactivity studies of covalent inhibitors derived from (-)-Chaetominine
Zhou, X., Feng, X., Wang, D., Chen, D., Wu, G., Yan, Z., Lyu, X., Wang, H., Yang, J.-M., & Zhao, Y. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.130694 · Cited by 5
Aljoundi, A., El-Rashedy, A. A. E., & Soliman, M. E. S. (2021) · Molecular Simulation · doi:10.1080/08927022.2021.1949457 · Cited by 5
Covalent Inhibition of the Human 20S Proteasome with Homobelactosin C Inquired by QM/MM Studies
Serrano-Aparicio, N., Ferrer, S., & Świderek, K. (2022) · Pharmaceuticals · doi:10.3390/ph15050531 · Cited by 6
BIreactive: Expanding the Scope of Reactivity Predictions to Propynamides
Hermann, M. R., Tautermann, C. S., Sieger, P., Grundl, M. A., & Weber, A. (2023) · Pharmaceuticals · doi:10.3390/ph16010116 · Cited by 5
Beckmann, L., Ließmann, F., Icker, M., RIEGER, D. L., Schlegel, P., Urban, N. D., Schaefer, M., Meiler, J., Schoeder, C. T., & Tretbar, M. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118093 · Cited by 4
Wei, W., Hu, Z., Gao, J., Yang, T., Zhang, Q., Xu, K., Qin, C., Lin, Y., Wang, N., Cao, Y., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118212 · Cited by 4
Sekrecki, M., Sekrecka, A., Lattupally, R., Le, K., Jin, X., Mozes, C., Dwyer, B. G., Zhuang, Z., Romero, B., Pineda, J. M. B., et al. (2026) · Blood · doi:10.1182/blood.2025029972 · Cited by 4
Huang, Y., Liu, M., Fan, D., Xu, F., Xiang, F., Min, Q., & Ji, X. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c00226 · Cited by 4
Wu, Y., Chen, Y., 曹瑞恆, Li, X., & Zhang, X. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03241 · Cited by 5
Wang, P., Li, Y., Yang, J., Li, Z., Ren, X., Meng, Q., Li, P., Qin, L., Li, W., Xie, Y., et al. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00281 · Cited by 4
Covalent Inhibitors - An Overview of Design Process, Challenges and Future Directions
Mugisa, S., & Murahari, M. (2025) · Current Organic Chemistry · doi:10.2174/0113852728361926250123092017 · Cited by 5
Wang, Y., Luo, S., Sun, H., Huang, S., Shan, L., & Zhang, J.-F. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104347 · Cited by 4
Olosunde, A., & Hu, X. (2025) · Molecules · doi:10.3390/molecules30102174 · Cited by 4
Investigating the Metabolic Mechanisms of Butaselen, An Ebselen Analog
Tian, Q., Jiang, J., Yin, H., Zhang, Y., Li, Y., Wu, P., Peng, C., Wang, Z., Zhou, J., Zeng, H., et al. (2022) · Current Drug Metabolism · doi:10.2174/1389200223666220520115014 · Cited by 4
Townsend, P. A., Farrar, E. H. E., & Grayson, M. N. (2022) · ACS Omega · doi:10.1021/acsomega.2c03739 · Cited by 4
Liu, X., Wang, B., Liu, Y., Yu, Y., Wan, Y., Wu, J., & Wang, Y. (2023) · Molecular Diversity · doi:10.1007/s11030-023-10742-3 · Cited by 4
Ligand-Based Design of Selective Peptidomimetic uPA and TMPRSS2 Inhibitors with Arg Bioisosteres
Müller, P., Zimmer, C., Frey, A. F., Holzmann, G., Weldert, A. C., & Schirmeister, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031375 · Cited by 4
Gu, Z., Yan, Y. J., Liu, H., Wu, D., Yao, H., Lin, K., & Li, X. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c01900 · Cited by 4
Deng, L., Li, S., Zhang, C., Zhou, Y., Su, Z., Hu, C., Zhao, X., & Yu, Z. (2024) · Organic Chemistry Frontiers · doi:10.1039/d4qo01870b · Cited by 4
An Unbiased Immunoaffinity-Based Strategy for Profiling Covalent Drug Targets In Vivo
Wang, X., Wang, X., Pu, X., Pu, W., Wang, Y., Liu, Y., Gong, Y., Jin, X., Peng, Y., & Dai, L. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b04118 · Cited by 4
Chandrasekaran, B., Al-Joubi, H., Samarneh, S., Kassab, G. H., Deb, P. K., Kumar, P., Al-Jaidi, B. A., Thaher, Y. A., & Bataineh, Y. A. (2020) · Springer eBooks · doi:10.1007/978-981-15-3556-7_2 · Cited by 4
Sacco, G., Stammwitz, S., Belvisi, L., Pignataro, L., Corso, A. D., & Gennari, C. (2021) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202100160 · Cited by 4
Detection of an enzyme isomechanism by means of the kinetics of covalent inhibition
Adediran, S. A., Morrison, M. J., & Pratt, R. F. (2021) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2021.140681 · Cited by 4
Salazar-Estrada, I. D. J., Kamath, K. S., & Liu, F. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00155 · Cited by 4
Scheiber, N., Blaser, G., Pferschy‐Wenzig, E., Kaiser, M., Mäser, P., & Presser, A. (2022) · Molecules · doi:10.3390/molecules27196559 · Cited by 4
Systematic Targeting of Protein Complexes with Molecular COUPLrs
Yang, D., Harry, S. A., Chong, H. B., Khandelwal, N., Zhang, E., Nordenfelt, N. S., Chen, N. J., Lee, C., Kaluziak, S. T., Codd, E. M., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-2314 · Cited by 4
Covalent Protein Inhibitors via Tyrosine Conjugation with Cyclic Imine Mannich ElectrophilesPreprint
Wang, S., Hadisurya, M., Tao, W. A., Dykhuizen, E. C., & Krusemark, C. J. (2022) · ChemRxiv · doi:10.26434/chemrxiv-2022-tvgn1 · Cited by 7
Asmare, M. M., Dhal, A. K., Mahapatra, R. K., & Yun, S. (2025) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2024.2446664 · Cited by 3
Meehan, M. C., Scofield, G. E., Stahl, C. E., Wolfe, J. A., Horne, W. S., Liu, P., & Brummond, K. M. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00833 · Cited by 3
Ferenczy, G. G., & Keserű, G. M. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104454 · Cited by 3
Dilweg, M. A., Widjaja, T., IJzerman, A. P., & van der Es, D. (2025) · Medicinal Research Reviews · doi:10.1002/med.70009 · Cited by 3
Mukherjee, S., Fried, S. D. E., Hong, N. Y., Bagheri, N., Kozuch, J., Mathews, I. I., Kirsh, J. M., & Boxer, S. G. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c14498 · Cited by 3
Ai, Y., Yang, Z., Yang, Z., Wan, S., Huang, C., Huang, C., Li, M., Li, Z., Zhang, J., & Zhang, T. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00458 · Cited by 3
Srinivasan, B. (2023) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2023.08.004 · Cited by 3
4‐Aza Cyclopentenone Prostaglandin Analogues: Synthesis and NF‐κB Inhibitory Activities
Doherty, W., Conway, L., Leveau, B., Nacca, F. G., Chiappa, L., Riccio, A., Roberts, S. M., Santoro, M. G., & Evans, P. (2024) · ChemMedChem · doi:10.1002/cmdc.202400823 · Cited by 3
Metabolism of new drug modalities research advances – 2024 year in review
Ma, B., Argikar, U. A., Chen, L., Cheruzel, L., Cho, S., Gu, T., Hauri, S., Kramlinger, V. M., Li, X., Liu, J., et al. (2025) · Drug Metabolism Reviews · doi:10.1080/03602532.2025.2542220 · Cited by 3
Activation and inhibition of the C-terminal kinase domain of p90 ribosomal S6 kinases
Fruergaard, M. U., Nielsen, C. J. F., Rosada, C., Iversen, L., Andersen, J. L., & Nissen, P. (2023) · Life Science Alliance · doi:10.26508/lsa.202201425 · Cited by 3
Kuttenlochner, W., Beller, P., Kaysser, L., & Groll, M. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107646 · Cited by 3
Takubo, H., Taniguchi, T., Iwanaga, K., & Nomura, Y. (2020) · Xenobiotica · doi:10.1080/00498254.2020.1805816 · Cited by 3
Structure-activity relationships of cysteine protease inhibitors
Rocho, F. D. R. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.75.2020.tde-17022020-135630 · Cited by 5
An Activity-Guided Map of Electrophile-Cysteine Interactions in Primary Human Immune CellsPreprint
Vinogradova, E. V., Lazar, D. C., Suciu, R. M., Wang, Y., Bianco, G., Yamashita, Y., Crowley, V. M., Remillard, D., Lum, K. M., Simon, G. M., et al. (2019) · SSRN Electronic Journal · doi:10.2139/ssrn.3476689 · Cited by 3
Ji, L., Liu, M., Yu, S., Wu, Z., & Chen, B. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.143016 · Cited by 2
Yang, Y., Jiang, Y., Zhang, D., Zhang, L., & Zhou, R. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c01307 · Cited by 2
Wang, Z., Wang, X., Li, Y., Li, P., Huang, S., Chen, P., Tang, G., Ding, X., Zhang, Z., Zhang, Z., et al. (2025) · Angewandte Chemie · doi:10.1002/ange.202510763 · Cited by 4
Wang, H., Guo, Y.-M., Yang, J., Cao, C., Ren, J.-N., Ye, H.-Y.-X., & Chen, J. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c01238 · Cited by 2
Chen, J., Qi, S., Lin, Z., Fang, H., Zhang, P., Li, W., Ge, R.-S., & Wang, Y. (2025) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2025.111888 · Cited by 2
BTK inhibitors in multiple sclerosis: emerging evidence and future directions
Zanetta, C., Rocca, M. A., & Filippi, M. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2634204 · Cited by 2
Ultrasound-guided and activated nanodrugs for highly selective tumor therapy
Luo, C., Liu, Y., Zhao, W., Du, J., 谈文叶, Xu, Y., Tang, Z., & Chen, X. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114755 · Cited by 2
Carbamoyl fluorides as serine hydrolase inhibitors: a case study on FphI from Staphylococcus aureus
Randall, G., Meden, A., Rutledge, M. T., Prestreši, L., Hrast, M., Chen, S., Zdovc, I., Gobec, S., Knez, D., & Fellner, M. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109834 · Cited by 2
Kinetic Analysis of Irreversible Covalent Enzyme Inhibitors and Its Use in Drug Design
Chaudière, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083383 · Cited by 2
Covalent Targeting of Histidine Residues: A Ligand-First Approach
Alboreggia, G., Atienza, E. L., Muzzarelli, K. M., Assar, Z., & Pellecchia, M. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03255 · Cited by 2
Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis
Lambe, J., & Fox, R. J. (2026) · Drugs · doi:10.1007/s40265-026-02324-y · Cited by 2
ChemInform Abstract: Targeted Covalent Inhibitors for Drug Design
Baillie, T. A. (2016) · ChemInform · doi:10.1002/chin.201649244 · Cited by 2
Self-citationColombo, F., Smith, S. A., Lai, G. W., Nix, D., Smith, P. G., Schindler, J., & Rioux, N. (2019) · Xenobiotica · doi:10.1080/00498254.2019.1643941 · Cited by 2
The Discovery and Development of Transthyretin Amyloidogenesis Inhibitors: What are the Lessons?
Zhong, B., Huang, X., Zheng, Y., Guo, X., & Wu, L. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0248 · Cited by 2
Drug development of covalent inhibitors
Dahal, U. P., & Wahlstrom, J. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-817134-9.00009-x · Cited by 2
Covalency-enabled Drug Discovery is Redefining Druggability
McKenna, J. M., & Proctor, R. S. J. (2023) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2023.537 · Cited by 2
Gao, J., Jiang, D., Wang, H., & Wang, X. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00136 · Cited by 2
Rational Design Strategies in DNA‐Encoded Libraries for Drug Discovery
Wang, X., Li, L., Shen, X., & Lu, X. (2025) · Angewandte Chemie · doi:10.1002/ange.202511839 · Cited by 2
Podoll, T., Geisler, L., Parys, M. V., Hanson, G. D., & Reid, M. J. (2018) · Bioanalysis · doi:10.4155/bio-2018-0159 · Cited by 2
Chemical proteomics of reactive molecules
Wang, L., & Yao, X. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821433-6.00008-8 · Cited by 2
Aryl Fluorosulfate Based Inhibitors That Covalently Target the SIRT5 Lysine Deacylase**
Bolding, J. E., Martín‐Gago, P., Rajabi, N., Gamon, L. F., Hansen, T. N., Bartling, C. R. O., Strømgaard, K., Davies, M. J., & Olsen, C. A. (2022) · Angewandte Chemie · doi:10.1002/ange.202204565 · Cited by 2
Awoonor‐Williams, E., & Rowley, C. N. (2020) · ChemRxiv · doi:10.26434/chemrxiv.13132814 · Cited by 2
A Perspective on Covalent Inhibitors: Research and Development Trends of Warheads and TargetsPreprint
Chen, H., Bird, R. E., Wang, D.-S., Diaz, L. M. L., Iyer, K. A., Ralhan, K., Gustafson, G. R., Kato-Weinstein, J., & Zhou, Q. A. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-wf79n · Cited by 4
Identification of Covalent Ligands – from Single Targets to Whole Proteome
Ngo, C., Ekanayake, A. I., & Zhang, C. (2023) · Israel Journal of Chemistry · doi:10.1002/ijch.202200105 · Cited by 1
Discovery of Novel Covalent Inhibitors of DJ-1 Through Hybrid Virtual Screening
Ma, Y., Song, Y., Wang, J., Shi, X., Yuan, Z., Li, S., Li, H., Chen, Z., & Li, S. (2024) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0301 · Cited by 1
Design and Synthesis of Novel MEK Inhibitors for the Treatment of Solid Tumors
Zeng, J., Luo, Z., Zhao, T., Xia, C., Liu, F., Li, N., Qu, L., & Wang, C. (2025) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70067 · Cited by 1
Zhang, Y., Liang, Z., Wang, S., Qiao, R., & Li, C. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117479 · Cited by 1
Drug discovery technologies–Current and future trends
Noe, M. C., Steppan, C. M., & Weston, A. D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00019-4 · Cited by 1
Use of new approach methodology for hepatic safety assessment of covalent inhibitor drug candidates
Amberntsson, S., Foster, A. J., Chouhan, B., Wilkinson, S. D., Harlfinger, S., Smith, G., Kettle, J. G., Niedbala, M. J., Kavanagh, S. L., & Williams, D. P. (2025) · Toxicology Research · doi:10.1093/toxres/tfaf054 · Cited by 1
Ouyang, X., Chai, X., Huang, L., Chen, Y., Li, S., Huang, W., Li, Y.-F., Ding, K., Liu, T., Tan, Y., et al. (2025) · Angewandte Chemie · doi:10.1002/ange.202504813 · Cited by 4
Shen, R., Zhang, B., Liu, J., Yi, M., Chen, Y., & Fang, J. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb01090j · Cited by 1
Proteome-Wide Ligand and Target Discovery by Using Covalent Probes and Natural Products
Liu, J. R., Huang, C., Li, S., Peng, L., Sun, Y., Yang, J., Li, S., Xu, S., Lu, X., Ding, K., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01277 · Cited by 1
Fatima, I., Safhi, A. Y., Alsalhi, A., Hanbashi, A., Jali, A. M., Alsabei, H. M., Alshabrmi, F. M., & Sabei, F. Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152973 · Cited by 1
Discovery of a Covalent Small-Molecule eEF1A1 Inhibitor via Structure-Based Virtual Screening
Deng, Y., Li, S. P., Wang, L., Lin, J., Fu, H., Li, J., & Chen, Y. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c02496 · Cited by 1
Li, R., Shi, Q., Zhu, M., Cao, W., Tao, Y., & Shen, L. (2026) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2026.100239 · Cited by 1
Group Competition Strategy for Covalent Ligand Discovery
Guo, Z., Meng, Y., Zhao, B., Xiao, W., & Wang, C. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.5c18150 · Cited by 1
Zhao, X., Wei, N., Fang, Z., Xie, Y., Yan, X. Y., & Wang, Q. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02215 · Cited by 1
Leng, J., Huang, Z., Zheng, L., Yang, Y., Huang, H., Gao, Y., Huo, L., Li, Y., Sun, Z., & Zhang, J. Z. H. (2026) · Physical Chemistry Chemical Physics · doi:10.1039/d5cp04981d · Cited by 1
Wang, Z., Jing, X., Liu, Q., Xian, T., Yang, J., Zhang, M.-Y., Li, Q.-Q., Cai, J., Yu, Y., Sun, S., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00511 · Cited by 1
Petri, L., Gabizon, R., Péczka, N., Ábrányi‐Balogh, P., Simon, J., Imre, T., Ferenczy, G. G., London, N., & Keserű, G. M. (2026) · Nature Communications · doi:10.1038/s41467-026-72993-6 · Cited by 1
Schwer, M., Aldea, S., Engelhardt, M., Stahlecker, J., Rheinganz, J., Langkamp, A., & Boeckler, F. M. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s598622 · Cited by 1
Developments in the design and therapeutic applications of GSK3β inhibitors
Daoud, S., & Taha, M. O. (2026) · Future Medicinal Chemistry · doi:10.1080/17568919.2026.2675873 · Cited by 1
Cai, Y., & Zhao, C. (2026) · Advanced Science · doi:10.1002/advs.202524277 · Cited by 1
Chemical Space Exploration of a Database of Covalent Binders in the PDB
Velasco-Saavedra, M. A., Mar-Antonio, E., Colorado-Pablo, L. F., Santos‐Contreras, M. Á., Flores-León, C. D., Carreón-Escalante, M., Sánchez-Maza, S., Ambrosio-Huerta, A., Goode‐Romero, G., Medina‐Franco, J. L., et al. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6c00846 · Cited by 1
Masuda, I., Baugh, S. D. P., McClay, K., Ford, R. J., Tayag, L., Strobel, E. D., Grant, T., DeSando, S. A., Guo, H., Christian, T., et al. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6c00164 · Cited by 1
Covalent Inhibitors in Antimicrobial Drug Development—Beyond β-Lactams
Jafari, G., & Duncan, D. (2026) · Molecules · doi:10.3390/molecules31122186 · Cited by 1
A multicomponent reaction-enabled discovery platform reveals a TXNRD1-targeted ferroptosis inducer
Fu, X., Wu, Q., Wu, S., Niu, G., Zhang, Z., Lin, Y., Cao, Y., Li, Y., Xiong, F., Qian, Y., et al. (2026) · The Innovation Drug Discovery · doi:10.59717/j.xinn-drugdisc.2026.100011 · Cited by 1
Preclinical characterization of a reversible XPO1 inhibitor for cancer therapy
Hauwenhuyse, J. V., Reniers, F., Persoons, L., Noppen, S., Wing, C. E., Niesman, A. B., Fung, H. Y. J., Vanstreels, E., Jacquemyn, M., Boel, E., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-75741-y · Cited by 1
Enhancing De Novo Designed Peptides and Proteins via Irreversible Covalent Isoquinolinium Capture
Levine, P. M., Erickson, P. W., Craven, T. W., Balana, A. T., Hicks, D. R., Ahn, G., Kim, C. J., Brandenburg, L. S., Yang, W., Erickson, D. P. J., et al. (2026) · ACS Chemical Biology · doi:10.1021/acschembio.6c00584 · Cited by 1
Ledezma, C. E., Cornett, E. M., & Kolpashchikov, D. M. (2020) · ACS Omega · doi:10.1021/acsomega.9b03942 · Cited by 1
Takubo, H., Ishikawa, T., Taniguchi, T., Iwanaga, K., & Nomura, Y. (2020) · Xenobiotica · doi:10.1080/00498254.2020.1809030 · Cited by 1
Metadata
- Authors
- Baillie, T. A.
- Affiliations
- University of Washington (US)
- Corresponding author
- Baillie, Thomas A.
- ORCID
- Baillie, Thomas A.
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2016-08-19
- Volume
- 55
- Issue
- 43
- Pages
- 13408-13421
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- OpenAlex
- W2517550655
- Cited by
- 578
- References
- 118
- Citations by year
- 2026: 55 · 2025: 77 · 2024: 66 · 2023: 46 · 2022: 49 · 2021: 76 · 2020: 72 · 2019: 52 · 2018: 46 · 2017: 31 · 2016: 5
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Angewandte Chemie International Edition (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- targeted covalent inhibitors, covalent drug design, drug toxicity, enzyme inhibitors, receptor modulators, drug discovery, non-covalent binding
- MeSH terms
- Animals, Enzyme Inhibitors, Humans, Ligands, Protein Kinases, Drug Design, Molecular Structure, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.